1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MapLight Therapeutics reported topline results from its Phase 2 IRIS trial of ML-004 in autism spectrum disorder, announced June 22, 2026. The study did not meet its primary endpoint on social communication deficits, but a prespecified analysis in adolescents with moderate-to-severe irritability showed improvement over placebo, and the company plans to meet with the FDA to determine the development path.
Primary endpoint (ABI-SC social communication domain) was not met; no statistical separation from placebo on that measure.
In adolescents with baseline ABC-I score of 16 or higher (N=20), care-partner-reported ABC-I improved over placebo: effect size 1.33, nominal p=0.013.
Two adolescents (3.9%) on ML-004 discontinued due to an adverse event versus none on placebo; no severe or serious adverse events occurred with ML-004.
The company expects to engage the FDA in an End-of-Phase 2 meeting; the trial enrolled 161 participants, including 102 adolescents.
HawkEye 360 reported first quarter 2026 results for the period ended March 31, with record revenue of $49.8 million, up 116.5% from $23.0 million a year earlier. The net loss widened to $9.0 million from $1.6 million, and backlog fell to $285.0 million from $302.7 million at year-end 2025. The company also completed an initial public offering in May 2026 that generated $435.9 million in net proceeds, and it will provide its 2026 outlook with its second quarter results.
Total revenue was $49.8 million, up 116.5% from $23.0 million in the prior-year period.
Net loss was $9.0 million, compared with $1.6 million a year earlier; adjusted EBITDA, a non-GAAP measure, was $7.4 million.
Backlog was $285.0 million at March 31, 2026, down from $302.7 million at December 31, 2025.
The IPO sold 18.4 million shares at $26.00 per share, generating net proceeds of $435.9 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.